Bharat Biotech’s US partner Ocugen submits ‘Master File’ to FDA on Covaxin


PTI, May 25, 2021, 1:03 PM IST

New Delhi: Ocugen, Bharat Biotech’s American partner for Covid-19 vaccine Covaxin, has submitted a “Master File” to the US Food and Drug Administration prior to seeking an emergency use authorisation in that country. “The company is currently evaluating the clinical and regulatory path for Covaxin in the United States including obtaining Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA).

Also, eventually biologic license application (BLA) approval in the United States, as well as the company’s commercialization strategy, if authorized or approved,” Ocugen has said in a recent regulatory filing. Ocugen has submitted key information and data to date including preclinical studies, chemistry, manufacturing, and controls (CMC), and clinical studies as a Master File for FDA review and input prior to a planned EUA submission.

The company is currently awaiting additional data from Bharat Biotech from the ongoing Phase 3 clinical trial for a EUA submission, it further said. Bharat Biotech on February 2 said it has entered into a definitive agreement with OcugenInc, a US-based biopharmaceutical company, to co-develop, supply, and commercialise, the Indian vaccine maker’s Covaxin for the US market.

Under the terms of the agreement, Ocugen will have US rights to the vaccine candidate and will be responsible for clinical development, regulatory approval including Emergency Use Authorisation and commercialization for the US market. The Indian government’s temporary suspension of the export of Covid-19 vaccines may require Bharat Biotech to focus its resources, including Covaxin supply, on domestic requirements and thereby prevent it from shipping supply of the vaccines abroad, including to the United States, the American company said in the risk factors.

“We are currently waiting for additional data from Bharat Biotech from the ongoing Phase 3 clinical trial for an EUA submission. Due to the current surge in Covid-19 cases in India, this process is taking longer than anticipated.

We are continuing to monitor the situation and intend to file the EUA submission as soon as practicable. Any significant delays could adversely affect our business, results of operations, or financial condition,” Ocugen said.

In an investor presentation, Ocugen said it is expecting the vaccine to be rolled out in the US during the second half of the current year. The initial US supply will be done by Bharat Biotech upon receiving authorisation from the FDA and also there will be technology transfer to US facilities. Ocugen is targeting 100 million doses per annum beginning 2021.

Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.

Top News

India abstains, Russia vetoes UNSC resolution on Moscow’s ‘illegal referenda’ on Ukraine

Gujarat: Rs 25.80-crore fake notes from ‘Reverse Bank of India’ seized in Surat

Withdrawal date not over, don’t know if there will be Cong prez poll on Oct 17: Jairam Ramesh

Periyapatna: Accident victim declared brain dead, 12 organs to be donated

Mangaluru: Customs officials at MIA seize gold worth Rs. 86,09,730 from Sep 25 to 30

Bharat Jodo Yatra: A new Rahul Gandhi & Congress have emerged, says Jairam Ramesh

Pakistan arrests 16 Indian fishermen


Related Articles More

Luxury hotel The Ocean Pearl, Ujire opens its doors for patrons

Vertex Workspace receives “Best Innovative Enterprise Award-2022”

RBI hikes benchmark lending rate by 50 basis points to rein in inflation

Markets fall in early trade

Reliance Jio Chairman Akash Ambani, OnlyFans’ CEO Amrapali Gan among TIME100 Next list of rising stars

MUST WATCH

Special story on elephant mahindra |Mysore Dasara

Day5 navaratri

Chief minister condemns Siddaramaiah’s ban on RSS statement

How to make dairy farm shed

Dasara Special : Family celebrating Gombe pooja since 50 years


Latest Additions

India vs SA match at Guwahati ‘sold out’

India abstains, Russia vetoes UNSC resolution on Moscow’s ‘illegal referenda’ on Ukraine

Gujarat: Rs 25.80-crore fake notes from ‘Reverse Bank of India’ seized in Surat

Mundra port drug haul case: Accused held from Delhi remanded in NIA custody till Oct 7

Withdrawal date not over, don’t know if there will be Cong prez poll on Oct 17: Jairam Ramesh

Thanks for visiting Udayavani

You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.